Kymera Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety covalently linked to interleukin-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety reported to be useful for the treatment of cancer.
Biogen Inc. and C4 Therapeutics Inc. have disclosed proteolysis targeting chimera (PROTAC) compounds comprising a degradation signaling moiety such as E3 ubiquitin ligase-binding moiety covalently linked to a Bruton tyrosine kinase (BTK)-targeting moiety through a linker reported to be useful for the treatment of leukemia and lymphoma, multiple sclerosis, atopic dermatitis, rheumatoid arthritis and systemic lupus erythematosus.
Onxeo SA has expanded its pipeline of drug candidates with OX-425, an optimized new compound of the OX-400 series sourced from its proprietary Platon platform.
Ischemic stroke comprises about 87% of stroke incidence. The nuclear factor κ B (NF-κB) cascade is a major regulatory pathway of inflammation and is activated in response to ischemic stroke in humans and in rodents during middle cerebral artery occlusion (MCAO).
Investigators at West China Hospital, Sichuan University and affiliated organizations have discovered a novel c-Myc inhibitor being developed as a potential anticancer agent.
Researchers from Jecho Laboratories Inc. and Shanghai Jiao Tong University reported the discovery of a novel anti-PD-L1/CXCR4 bispecific nanobody, BsNb PX-4, being developed for the treatment of cancer.
Retrotransposons could have a main role in the development of drug resistance in response to cancer treatment, according to a new study out of the Roswell Park Comprehensive Cancer Center. The transposition of DNA elements triggers an inflammatory response involved in the survival of cancer cells, a mechanism that could be blocked applying reverse transcriptase inhibitors, a class of drugs better known as anti-HIV medications.
Eikonoklastes Therapeutics Inc. and Forge Biologics Inc. have established a manufacturing partnership to advance Eikonoklastes' adeno-associated viral (AAV)-based gene therapy, ET-101, into clinical trials for the treatment of patients with amyotrophic lateral sclerosis (ALS).
CSPC Pharmaceutical Group Ltd. has received IND approval from the FDA for a phase I study in the U.S. of its antibody-drug conjugate CPO-204 in patients with locally advanced or metastatic urothelial cancer.
RSS
